Literature DB >> 2205423

The independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein profiles in women.

M J Graf1, C J Richards, V Brown, L Meissner, A Dunaif.   

Abstract

We performed this study to clarify the independent effects of hyperandrogenaemia, hyperinsulinaemia, and obesity on lipid and lipoprotein levels in women with hyperandrogenaemia (HA) and anovulation which we designated as the polycystic ovary syndrome (PCO). We examined fasting lipid, lipoprotein, sex hormone and insulin levels in 38 women (21 obese (ob), 17 non-obese (nob] with HA and anovulation (PCO) and 38 normal ovulatory women (21 obese, 17 non-obese), matched for age and weight. The women with PCO had significantly increased androgen levels compared to the normal women. However, total oestradiol levels were similar in the PCO and normal women. Mean fasting insulin levels and 2-h glucose levels (both P less than 0.001) were significantly higher in ob PCO women. There were significant decreases (P less than or equal to 0.01) in high-density lipoprotein (HDL) levels in both the obese groups (ob PCO and ob normal) compared to the non-obese (nob PCO and nob normal) groups. Otherwise, mean lipid and lipoprotein levels did not differ in the ob or the nob PCO women compared to the control groups. The correlations between sex hormone, lipid and lipoprotein levels differed in the four groups of women. After statistical adjustment for potential hormonal interactions, nob PCO women had significant positive correlations between testosterone and LDL levels (R = 0.51, P less than 0.05) and insulin and TTG levels (R = 0.61, P less than 0.01). Ob normal women had a significant positive correlation between oestrone and TTG levels (R = 0.44, P less than or equal to 0.05). We conclude that (1) PCO women are in a low to risk for CVD primarily because of the increased prevalence of obesity rather than the reproductive hormone abnormalities associated with this disorder. However, by their lipid profiles, the PCO women were still in a low to intermediate risk group for CVD.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2205423     DOI: 10.1111/j.1365-2265.1990.tb00472.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

1.  Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.

Authors:  Susan Sam; Richard S Legro; Paulina A Essah; Teimuraz Apridonidze; Andrea Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

2.  Hirsutism.

Authors:  G S Conway; H S Jacobs
Journal:  BMJ       Date:  1990-09-29

3.  Lipid profile in relation to anthropometric indices and insulin resistance in overweight women with polycystic ovary syndrome.

Authors:  Maryam Saghafi-Asl; Saeed Pirouzpanah; Mehranghiz Ebrahimi-Mameghani; Mohammad Asghari-Jafarabadi; Soudabeh Aliashrafi; Bita Sadein
Journal:  Health Promot Perspect       Date:  2013-12-31

Review 4.  How actual is the dietary treatment in overweighting patients with polycystic ovary syndrome?

Authors:  C Cortet-Rudelli; D Dewailly
Journal:  J Endocrinol Invest       Date:  1998-10       Impact factor: 4.256

Review 5.  PCOS Forum: research in polycystic ovary syndrome today and tomorrow.

Authors:  Renato Pasquali; Elisabet Stener-Victorin; Bulent O Yildiz; Antoni J Duleba; Kathleen Hoeger; Helen Mason; Roy Homburg; Theresa Hickey; Steve Franks; Juha S Tapanainen; Adam Balen; David H Abbott; Evanthia Diamanti-Kandarakis; Richard S Legro
Journal:  Clin Endocrinol (Oxf)       Date:  2011-04       Impact factor: 3.478

6.  Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome.

Authors:  Susan Sam; Richard S Legro; Rhonda Bentley-Lewis; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2005-05-17       Impact factor: 5.958

Review 7.  Cardiovascular complications of obesity in adolescents.

Authors:  F Orio; S Palomba; T Cascella; S Savastano; G Lombardi; A Colao
Journal:  J Endocrinol Invest       Date:  2007-01       Impact factor: 4.256

8.  Determinants of dyslipidaemia in probands with polycystic ovary syndrome and their sisters.

Authors:  Jalini Joharatnam; Thomas M Barber; Lisa Webber; Gerard S Conway; Mark I McCarthy; Stephen Franks
Journal:  Clin Endocrinol (Oxf)       Date:  2011-06       Impact factor: 3.478

9.  Anteroposterior diameter of the infrarenal abdominal aorta is higher in women with polycystic ovary syndrome.

Authors:  Marco Matteo Ciccone; Stefano Favale; Anish Bhuva; Pietro Scicchitano; Vito Caragnano; Cristina Lavopa; Giovanni De Pergola; Giuseppe Loverro
Journal:  Vasc Health Risk Manag       Date:  2009-06-29

10.  Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome.

Authors:  P A Essah; J E Nestler; E Carmina
Journal:  J Endocrinol Invest       Date:  2008-01       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.